Symbols

AEON

AEON Biopharma·AMEX

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 0

Consensus Rating "Strong Buy"

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AEON

Aeon Biopharma, Inc.

A biopharmaceutical company, develops botulinum toxins for the treatment of debilitating medical conditions

Industry

Pharmaceutical

Established Date

Listing Date

07/24/2023

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.aeonbiopharma.com

Security Type

Common stock

Office address

5 Park Plaza, Suite 1750, Irvine, California 92614

Business

Introduction

AEON Biopharma, Inc., was incorporated in Delaware in February 2012. The Company is a clinical-stage biopharmaceutical company focused on the development of the proprietary botulinum toxin complex ABP-450 for debilitating medical conditions, with an initial focus on the neuroscience market. The company has completed a Phase 2 study of ABP-450 for cervical dystonia and is conducting a Phase 2 study of ABP-450 for chronic and episodic migraine. Top-line data from the episodic migraine cohort of the Phase 2 study was reported in October 2023, and the chronic migraine cohort is still in progress. ABP-450 is a botulinum toxin conjugate currently approved and marketed by Evolus under the name jeuveau for cosmetic indications. ABP-450 is manufactured by Daewoong in cGMP in facilities approved by the FDA, Health Canada and EMA. The company has exclusive development and distribution rights for ABP-450 therapeutic indications in the US, Canada, the EU, the UK and certain international regions. The company has built an experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.

Company Financials

EPS

AEON has released its 2025 Q3 earnings. EPS was reported at -0.39, versus the expected -0.43, beating expectations. The chart below visualizes how AEON has performed over recent quarters, highlighting trends in earnings surprises.